

ISICR Officers

President

Kathryn Zoon

President-Elect

Keiko Ozato

Secretary

Sidney Pestka

Treasurer

Sam Baron



September 2001

Volume 8, No. 3

Future ISICR Meetings

Oct. 7 - 11, 2001

Cleveland, OH

<http://www.isicr2001.org>

Oct. 6 - 11, 2002

Torino, Italy

Joint ISICR/ICS/SLB/ECS

2003

Cairns, Australia

ISICR WWW Site

www.ISICR.org

ISICR Business Office

ISICR@faseb.org

TEL: 301-571-8319

FAX: 301-530-7049

ISICR Newsletter Editors

Howard Young

youngh@mail.ncifcrf.gov

Fax: 301-846-1673

Pat Fitzgerald-Bocarsly

Bocarsly@umdnj.edu

Fax: 973-972-7293

Hannah Nguyen

nguyenh@cesmtp.ccf.org

Fax : 216-445-9769

2001 Milstein Award

Dr. Sidney Pestka

2001 Honorary Membership

Dr. Thomas Merigan

Milstein Young Investigator Awards

Betsy Barnes

Gary Geiss

Celine Gongora

Rune Hartmann

The Christina Fleischmann Memorial Award

Kristi Peters

ISICR 2001 Preliminary Program

Sunday, October 7

2:00-7:00 pm	On-site Registration
2:00-6:00 pm	ISICR Committee Meetings
3:00 pm	Cleveland Orchestra (tickets limited)
6:00-7:30 pm	Welcome, Introductions and Awards Milstein Award Lectures
7:30-9:30 pm	Taste of Cleveland Reception/Sheraton

Monday, October 8

8:00-11:30 am PLENARY 1. REGULATION OF CYTOKINE SIGNALING PATHWAYS

Chairpersons: Ian M. Kerr and Andrew C. Lerner

8:00	P1.1	<i>"JAK/STAT Signalling"</i> Ian Kerr
8:40	P1.2	<i>"IFN Signaling Dysfunction in Cancer"</i> Robert Schreiber
9:10	P1.3	<i>"The role of STAT1 in T cell function"</i> Michael David
9:40	P1.4	<i>"The role of Src family kinases in cellular signal transduction pathways"</i> Sarah Courtneidge
10:10		Break
10:30	P1.5	<i>"The SOCS proteins as physiological inhibitors of cytokine signaling"</i> Nicos A. Nicola
11:00	P1.6	<i>"IFN stimulated transcription through protein deacetylase, TAFIII30 and the acetyltransferase GCN5 without TATA binding proteins escapes virus-mediated host shutoff"</i> David Levy

11:30 pm LUNCH (put up posters for Poster Session 1)

1:00 pm POSTER SESSION 1

2:30 pm BREAK

3:00-6:00 pm PLENARY 2. INTERFERONS, CYTOKINES AND IMMUNOREGULATION

Chairpersons: Richard A. Flavell and Richard M. Ransohoff

3:00	P2.1	<i>"Mechanisms that understand cytokine gene expression in T cells"</i> Richard A. Flavell
3:45	P2.2	<i>"Signaling by IL-12 and gc cytokines"</i> John O'Shea
4:10	P2.3	<i>CIITA: The master regulator and chromatin modifier of MHC promoters"</i> Jenny Ting
4:35		Break
4:45	P2.4	<i>"Chemokine Regulation of T Helper Cell Polarization"</i> Barrett Rollins
5:10	P2.5	<i>"IFNγ regulates the development and function of the monocyte-macrophage lineage through IRF-8 (ICSBP)"</i> Keiko Ozato
5:35	P2.6	<i>"Direct visualization of IFN-γ secretion by individual CD4 T cells: The extent of TCR stimulation defines the kinetics and the amount of the per cell produced cytokine"</i> Paul Lehmann

7:00 pm LERNER RESEARCH INSTITUTE RECEPTION/TOUR

Tuesday, October 9

8:00-11:30 am PLENARY 3. INTERFERONS, CYTOKINES AND CANCER


Chairpersons: John M. Kirkwood and Ronald M. Bukowski

8:00		Welcome/Introductions - Drs. Bukowski & Kirkwood
8:05	P3.1	<i>"Cytokine Therapy for Advanced Renal Carcinoma - Overview"</i> Bernard Escudier
8:35	P3.2	<i>"Chronic Myelogenous Leukemia - Therapy Update"</i> Moshe Talpaz
9:05	P3.3	<i>"High-dose Interferon: Effective standard therapy and basis for the development of future vaccines and combined modality chemotherapy"</i> John Kirkwood
9:35		Break
10:00	P3.4	<i>"FLIP Regulation of T-cell Apoptosis"</i> James Mier
10:30	P3.5	<i>"Stem cell products, immunologic recovery and CD4 apoptosis in stem cell transplantation"</i> James Talmadge
11:00	P3.6	<i>"The IFN-α/β system in immune response and oncogenesis"</i> Tadatsugu Taniguchi

11:30 pm LUNCH + POSTER SESSION 1

1:00-3:00 pm WORKSHOP 1. REGULATION OF CYTOKINE SIGNALING

Chairpersons: David Levy and Paula Pitha

- 1:00 W1.1 *"Requirement of PI3K for the induction of chemokine CXCL11/beta-R1 by IFN-beta"*
Rani MRS, Ransohoff RM
- 1:15 W1.2 *"IFN-alpha/beta promotes cell survival by activating NF-kappaB through PI-3K and AKT"*
Yang CH, Murti A, Pfeffer SR, Kim JG, Pfeffer LM
- 1:30 W1.3 **Christina Fleischmann Memorial Award for Young Women Investigators: Kristi Peters**
"NFkappaB-independent signaling by dsRNA: Involvement of PI-3 kinase"
Peters KL, Jin G, Stark GR, Sen GC 
- 1:45 W1.4 *"Interferon stimulated C/EBP beta mediated gene expression is STAT1 dependent and requires extracellular signal regulated kinases (ERK)"*
Roy SK, Hu J, Shapiro P, Rodig S, Schreiber RD, Kalvakolanu DV
- 2:00 W1.5 *"Physical and functional interaction of mitogen-activated protein kinase MKK6 and double-stranded RNA-dependent protein kinase PKR"*
Silva AM, Xu Z, Williams BRG
- 2:15 W1.6 *"The role of COP9/Signalosome complex as an integrator of signals that modulate ICSBP/IRF-8 transcriptional activity"*
Cohen T, Cohen H, Azriel A, Meraro D, Hashmueli S, Bech-Otschir D, Kraft, R, Dubiel W, Levi B-Z
- 2:30 W1.7 *"Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment"*
Masumi A, Ozato K
- 2:45 W1.8 *"IRAK functions as a scaffolding protein in IL-1 signaling"*
Li X, Jiang Z, Qian Y

1:00-3:00 pm WORKSHOP 2. CYTOKINES AND IMMUNE REGULATION

Chairpersons: Tom Hamilton and Howard Young

- 1:00 W2.1 *"Altering the T cell transcriptional response: Signaling through the chemokine receptor CXCR2"*
Hwu P, Kershaw M, Wang G, Tiffany HL, Murphy PM, Young HA
- 1:15 W2.2 *"Monocytes and type I IFN: A natural alliance for the generation of highly active dendritic cells"*
Di Pucchio T, Parlato S, Santini SM, Lapenta C, Logozzi M, Belardelli F
- 1:30 W2.3 *"Induction of Interferon-alpha/beta genes by pathogen-associated molecules"*
Takaoka A, Asagiri M, Honda K, Nakaya T, Hata N, Yanai H, Taniguchi T
- 1:45 W2.4 *"Does dsRNA signal through a toll like receptor mediated pathway?"*
de Veer M, Sledz C, DiDonato J, Williams BRG
- 2:00 W2.5 *"IL-10 inhibits inflammatory chemokine expression both transcriptionally and post-transcriptionally"*
Hamilton TA, Dai Y, Novotny M, Tebo J, DasGupta J
- 2:15 W2.6 *"An in vitro macrophage differentiation system initiated by ICSBP (IRF-8) and genome-wide gene expression analysis"*
Tamura T, Tanaka T, Tsujimura H, Uno T, Calame K, Ko, MSH, Ozato K
- 2:30 W2.7 *"Enhancement of DNA mediated immune responses by IRFs"*
Pitha PM, Yeow W-S, Sasaki S, Amar RR, Robinson HL
- 2:45 W2.8 *"Regulation of the IL-12 P40 promoter by human TLR4 receptor"*
Ronni T, Smale ST

3:00 pm **BREAK**

3:30-5:30 pm **WORKSHOP 3. INTERFERONS, CYTOKINES AND CANCER**

Chairpersons: Kathy Zoon and Eleanor Fish

- 3:30 W3.1 *“Activation of the p38 pathway mediates the growth inhibitory effects of interferon-alpha in chronic myelogenous leukemia cells”*
Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC
- 3:45 W3.2 *“Interferon-alpha promotes the differentiation of CD14+ monocytes from CML patients into active dendritic cells”*
Gabriele L, Rozera C, Borghi P, Sestili P, Guarini A, Cannella L, Foa R, Belardelli F
- 4:00 W3.3 *“Suppression of hepatocellular carcinoma development by an activatable interferon regulatory factor-1 in mice”*
Kroeger A, Geissler M, Hauser H
- 4:15 W3.4 *“The interferon-retinoid induced tumor cell death pathways: A grim story”*
Kalvakolanu DV, Ma X, Hu J, Karra S, Zhang J, Sridharan V, Lindner DJ, Kimchi A
- 4:30 W3.5 *“Interferon-alpha anti-tumor activity in non-Hodgkins’ lymphoma and multiple myeloma cells is controlled by endogenous and IFN-alpha-stimulated JAK-STAT signaling”*
Donato N, Sah N, Ford R, Talpaz M
- 4:45 W3.6 *“IFN-A2 and PEG-IFN-A2 inhibit tumor induced angiogenesis in the murine dermis model”*
Bauer JA, Grane RW, Jacobs B, Morrison BH, Borden EC, Lindner DJ
- 5:00 W3.7 *“Modulation of DC phenotype and mobility by malignant cells through ISG15”*
Padovan E, Jacobs B, Spagnoli GC, Heberer M, Certa U, Borden EC
- 5:15 W3.8 *“Tumor infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of tumor necrosis factor and nitric oxide”*
Frey AB, Radoja S, Saio M

3:30-5:30 pm **WORKSHOP 4. CYTOKINE RECEPTORS AND SIGNALING MOLECULES**

Chairpersons: Sandra Pellegrini and Sid Pestka

- 3:30 W4.1 *“Direct analysis of protein interactions in single cells in real time by fluorescence resonance energy transfer: Measuring receptor engagement at the molecular level and implications for high throughput screening and mapping proteomes”*
Pestka S, Krause CD
- 3:45 W4.2 *“A completely foreign receptor can efficiently mediate an interferon-gamma-like response”*
Strobl B, Arulampalam V, Newman SJ, Is’harc H, Watling D, Costa-Pereira AP, Schlaak JF, Schaper F, Behrmann I, Heinrich PC, Sheehan K, Kerr IM
- 4:00 W4.3 *“Interferon signaling is dependent on specific phosphotyrosines located within the intracellular domain of IFNAR2C. Expression of IFNAR2C phosphotyrosine mutants in U5A cells”*
Wagner TC, Vogel D, Rani, MRS, Leung S, Colamonici O, Ransohoff RM, Perez DH, Croze E
- 4:15 W4.4 *“Structural basis of receptor activation by IL-10”*
Josephson K, Logsdon N, Walter MR
- 4:30 W4.5 *“Structure of the interferon-receptor complex determined by distance constraint docking”*
Roisman L, Piehler J, Trosset J-Y, Scheraga HA, Schreiber G
- 4:45 W4.6 *“Constitutive gene activation by non-phosphorylated Stat2 is prevented by efficient CRM1-mediated nuclear export”*
Koster M, Hauser H
- 5:00 W4.7 *“STAT3: A tale of multiple NESs”*
Bhattacharya S, Schindler C

5:15 W4.8 *"Regulated cellular localization of the STAT1 transcription factor"*
McBride K, McDonald C, Banninger G, Reich NC

7:00-11:00 pm **ROCKHALL BANQUET**

Wednesday, October 10

8:00-11:30 am **PLENARY 4. INTERFERONS, CYTOKINES AND VIRUS-HOST INTERACTIONS**

Chairpersons: Christine A. Biron and Ganes C. Sen

8:00 P4.1 *"Immunoregulatory Functions for Type 1 Interferons During Viral Infections"* Christine Biron
8:40 P4.2 *"Activation of antiviral cascades by the IRF transcription factors"* John Hiscott
9:10 P4.3 *"Antiviral mechanism of human MxA GTPase and viral escape"* Otto Haller
9:40 Break
10:10 P4.4 *"Novel functions of proteins induced by IFNs, dsRNA and viruses"* Ganes Sen
10:40 P4.5 *"How poxviruses investigate cytokines"* Grant McFadden
11:10 P4.6 *"Regulation of the interferon-beta promoter during Hepatitis C virus RNA replication"* Michael Gale

11:30 am **LUNCH + POSTER SESSION 2**

1:00-3:00 pm **WORKSHOP 5. IFN-STIMULATED GENES AND THEIR FUNCTIONS**

Chairpersons: Chuck Samuel and Santo Landolfo

1:00 W5.1 *"Interferon-inducible double-stranded RNA-specific adenosine deaminase: Novel regulation and A-to-I editing of pre-mRNAs and double-stranded RNA"*
George CX, Liu Y, Wolff, KC, Maas S, Rich A, Jacobs BL, Samuel CE

1:15 W5.2 *"ADIR: A novel interferon responsive ATP binding protein related to the torsins"*
Dron M, Meritet J-F, Dandoy-Dron F, Meyniel J-P, Tovey MG

1:30 W5.3 *"Identification of the 2-5(A) binding sites of 2'-5' oligoadenylate synthetase"*
Sarkar SN, Pal S, Crabb JW, Sen GC

1:45 W5.4 *"STAT1 protects against IFN-alpha neurotoxicity caused by distinct signaling mechanisms"*
Wang J, Campbell IL

2:00 W5.5 *"Overexpression of the interferon-inducible protein p204 mutated at the Rb binding sites induces tumorigenicity in NIH3T3 cells"*
DeAndrea M, Rolle S, Noris E, Ying GG, Gioia D, Azzimonti B, Gariglio M, Landolfo S

2:15 W5.6 *"Interferon-gamma-mediated reduction in fibroblast spreading on fibronectin requires the IFN-induced GTPase, mGBP-2"*
Gorbacheva VY, Vestal DJ

2:30 W5.7 *"Interferon-induced MxA protein inhibits bunyavirus replication by sequestering the viral nucleocapsid protein into perinuclear complexes"*
Kochs G, Janzen C, Hohenberg H, Haller O

2:45 W5.8 *"The IFN-stimulated gene PLSCR1: A receptor & substrate of proto-oncogene c-Abl that inhibits tumor growth in vivo"*
Sims PJ, Silverman RH

1:00-3:00 pm **WORKSHOP 6. CYTOKINES AND INFECTIOUS DISEASES**

Chairpersons: Ara Hovanessian and Kendall Smith

1:00 W6.1 *"Therapeutic cytokines for the treatment of infectious diseases"*
Smith KA

1:15 W6.2 *"Liver-specific expression of cytokines transduced by recombinant duck hepatitis B virus"*
Schultz U, Schmohl K, Nassal M

- 1:30 W6.3 *“Endogenous levels of mRNA for type I-IFN and IFN-stimulated genes in liver biopsies of patients infected with different HCV genotypes”*
Abbate I, Romano M, Longo R, Cappiello G, Antonucci G, Paparella C, Ursitti A, Spano A, Capobianchi MR
- 1:45 W6.4 *“Evidence for distinct effects of PKR/RnaseL-dependent and alternative antiviral pathways upon initial infection of dendritic cells and virus dissemination”*
Ryman KD, White LJ, Johnston RE, Klimstra WB
- 2:00 W6.5 *“The growth factor midkine is a cytokine that inhibits HIV infection by an autocrine and paracrine action”*
Hovanessian AG, Nisole S, Said EA, Krust B
- 2:15 W6.6 *“Characterization of virus specific cytotoxic lymphocytes lacking Stat1”*
Durbin JE, Mertz SE, Johnson PR, Beall C, Walker C
- 2:30 W6.7 *“Induction of type I IFN gene transcription in dendritic cells infected by mycobacterium tuberculosis”*
 Remoli ME, Dondi E, Giacomini E, Iona E, Battistini A, Uze G, Pellegrini S, Coccia EM
- 2:45 W6.8 **Milstein Young Investigator Award: Rune Hartmann**
“The p59 oligoadenylate synthetase like protein (P59OASL) does not display oligoadenylate synthetase activity but possesses antiviral properties conferred by an ubiquitin-like domain”
Hartmann R, Rebouillat D, Justesen J, Sen GC, Williams BRG



3:00 pm BREAK

3:30-6:30 pm PLENARY 5. CYTOKINES AND APOPTOSIS
 Chairpersons: Theresa L. Whiteside and Ernest C. Borden

- 3:30 P5.1 *“Overview: Apoptosis signaling by death receptors”* Avi Ashkenazi
- 4:05 P5.2 *“Cytokines of the TNF family and the control of cell death”* Pascal Schneider
- 4:30 P5.3 *“TRAIL: Regulation of apoptosis”* David Lynch
- 4:55 P5.4 *“Cytokine-mediated T cell apoptosis”* Theresa Whiteside
- 5:15 P5.5 *“Cytokines and dendritic cell maturation”* Michael Shurin
- 5:35 P5.6 *“Tumor-induced Apoptosis of T cells”* James Finke
- 5:55 P5.7 *“Pro-apoptotic properties of GM-CSF in acute myeloid leukemia”* Zeev Estrov
- 6:10 P5.8 *“Identification of X-linked inhibitor of apoptosis-associated factor-1 (XAF1) as a critical determinant of cellular sensitivity to IFN-induced apoptosis”* Douglas Leaman

7:30 pm SPEAKERS’ DINNER, CCF FOUNDATION HOUSE

Thursday, October 11

8:00-11:30 am PLENARY 6. INTERFERONS, MULTIPLE SCLEROSIS AND OTHER NEUROLOGICAL DISEASES
 Chairpersons: Timothy Vartanian and Richard A. Rudick

- 8:00 Introduction - Tim Vartanian
- 8:05 P6.1 *“Toll-Like Receptors (TLRs) and Innate Immunity”* Doug Golenbock
- 8:35 P6.2 *“TLR4: The Link between infection and inflammatory injury to oligodendrocytes”* Tim Vartanian
- 9:05 P6.3 *“Interferon Beta In Multiple Sclerosis”* Richard Rudick
- 9:35 Break
- 10:00 P6.4 *“Co-Stimulatory signal blockade in MS: From bench to bedside”* Samia Khoury
- 10:30 P6.5 *“Shaping of the autoimmune T cell repertoire by IFN-beta in a murine model for multiple sclerosis”* Vincent Tuohy
- 11:00 P6.6 *“The Evidence Study: Direct comparative study of IFN beta-1a (Rebif 44 mcg thrice weekly and Avonex 30 mcg weekly) in RRMS”* Hillel Panitch
- 11:15 P6.7 *“Interferon-beta regulation of dendritic cell-derived cytokines”* Gijs van Seventer

11:30 am LUNCH + POSTER SESSION 2

1:00-3:00 pm WORKSHOP 7. IFN, CYTOKINES AND VIRUS: MECHANISMS OF RESISTANCE

Chairpersons: Bob Silverman and Michael Katze

- 1:00 W7.1 **Milstein Young Investigator Award: Gary Geiss**
"Hepatitis C virus and interferon resistance: A global view of NS5A mediated effects on cellular gene expression and attenuation of interferon stimulated gene expression"
Geiss GK, Carter VS, He Y, Nakao H, Bumgarner RE, Katze MG
- 1:15 W7.2 *"Acquisition of interferon resistance in hepatitis C virus RNA replicons"*
Sumpter RM, Gale M
- 1:30 W7.3 *"Inhibition of the immediate-early interferon production by the leader peptide of Theiler's virus"*
van Pesch V, van Eyll O, Michiels T
- 1:45 W7.4 *"Bunyavirus non-structural protein NSs antagonizes the cellular interferon system"*
Weber F, Bridgen A, Fazakerley JK, Elliott RM
- 2:00 W7.5 *"Vaccinia virus E3L suppresses the IFN system by preventing activation of antiviral enzymes and IRF3 phosphorylation"*
Xiang Y, Condit R, Vijaysri S, Jacobs B, Williams B, Silverman RH
- 2:15 W7.6 *"The neurovirulence factor g134.5 of herpes simplex virus 1 is required for viral resistance to interferon-alpha/beta"*
Cheng G, Brett M-E, He B
- 2:30 W7.7 *"Subversion of interferon system by KSHV-encoded vIRF-2 and vIRF-3"*
Lubyova B, Burysek L, Pitha PM
- 2:45 W7.8 *"Interplay between the cellular antiviral response and viral countermeasures: The ubiquitin-like ISG15 protein in influenza virus-infected cells"*
Yuan W, Kim M-J, Krug RM



1:00-3:00 pm WORKSHOP 8. REGULATION OF IFN AND CYTOKINE EXPRESSION

Chairpersons: Ray Kaempfer and Michel Revel

- 1:00 W8.1 *"Human IFN-gamma mRNA autoregulates its translation by strongly activating PKR"*
Ben-Asouli Y, Banai Y, Pel-Or Y, Shir A, Kaempfer R
- 1:15 W8.2 **Milstein Young Investigator Award: Celine Gongora**
"IFN gamma triggers interaction of ICSBP (IRF-8) with TEL, a transcription factor of the ETS family, and represses ISRE mediated transcription"
Gongora C, Kuwata T, Kanno Y, Sakaguchi K, Tamura T, Basur V, Appella E, Ozato K
- 1:30 W8.3 *"Characterization of the sequential treatment with IFN and dsRNA that abrogates virus resistance to IFN action"*
Sekellick MJ, Marcus PI
- 1:45 W8.4 *"The inhibitory effect of IL-1beta on IL-6 induced alpha2-macroglobulin expression is due to activation of NF-kappaB"*
Schaper F, Bode JG, Fischer R, Haussinger D, Graeve L, Heinrich PC
- 2:00 W8.5 *"Stimulation of myelin gene expression by IL6RIL6, an activator of gp130 signaling"*
Slutzky G, Kumar A, Levy A, Haggiag S, Zhang P, Shinder V, Chebath J, Revel M
- 2:15 W8.6 *"IFN-beta is critical for a host immune response to viral or tumor challenge"*
Deonarain R, Smith D, Gewert D, Porter A, Dawood F, Liu P, Fish E
- 2:30 W8.7 *"Transcriptional regulation of IL-18 binding protein gene expression"*



Hurgin V, Novick D, Rubinstein M

3:00 pm **BREAK**

3:30-5:30 pm **WORKSHOP 9. GENE REGULATION BY VIRUS INFECTION**

Chairpersons: Phil Marcus and Nancy Reich

- 3:30 W9.1 *"Apoptosis promoted by the dsRNA activated factor DRAFI/IRF-3 independent of the action of interferon on p53"*
Weaver BK, Kumar P, Ando O, Andersen J, Reich NC
- 3:45 W9.2 *"Induction of IRF-3/-7 kinase and NF-kappaB in response to double-stranded RNA and virus infection: Common and unique pathways"*
Iwamura T, Yoneyama M, Yamaguchi K, Suhara W, Mori W, Shiota K, Okabe Y, Fujita T
- 4:00 W9.3 **Milstein Young Investigator Award: Betsy Barnes**
"Virus-specific activation of interferon regulatory factor-5 and its unique role in the induction of IFNA genes"
Barnes BJ, Pitha PM
- 4:15 W9.4 *"Mechanism for transcriptional synergy between IRF-3 and IRF-7 in the activation of the interferon-beta gene promoter"*
Yang H, Lin CH, Ma G, Wathelet MG
- 4:30 W9.5 *"Herpes simplex virus triggers and then disarms a host antiviral response"*
Mossman KL, MacGregor PF, Rozmus JJ, Goryachev AB, Edwards AM, Smiley JR
- 4:45 W9.6 *"Large scale analysis of AU-rich element-containing mRNA expression and turnover using cDNA microarrays"*
Frevel MA, Bakheet T, Stookey K, Khabar KSA, Williams BRG
- 5:00 W9.7 *"Hepatitis C virus (HCV) infection is a widespread human health concern"*
Torgov M, Carter V, Geiss G, Lazaro C, Purvine S, Goodlet D, Katze M



3:30-5:30 pm **WORKSHOP 10. CYTOKINE REGULATION OF APOPTOSIS**

Chairpersons: Christine Czarniecki and Joan Durbin

- 3:30 W10.1 *"Effects of IFN-alpha on survival and proliferation of human primary B-lymphocytes"*
Ruuth K, Lundgren E
- 3:45 W10.2 *"Induction of Apo2L and modulation of Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma"*
Chen Q, Gong B, Mahmoud-Ahmed A, Zhou A, Hsi E, Hussein M, Almasan A
- 4:00 W10.3 *"Inhibition of protein synthesis by inducers of apoptosis: Differential requirements by the TNF alpha family and a DNA damaging agent for caspase and PKR protein kinase activities"*
Jeffrey IW, Bushell M, Tilleray VJ, Morley S, Clemens MJ
- 4:15 W10.4 *"Studies on properties and expression of PACT, a protein activator of PKR"*
Huang X, Gupta V, Patel RC
- 4:30 W10.5 *"Anti-apoptotic signaling mediated by the common gamma cytokine receptor"*
Lindemann MJ, Gaffen SL
- 4:45 W10.6 *"Apoptotic signaling pathways triggered by double-stranded RNA and encephalomyocarditis virus: A mechanism for rapid elimination of virus infected cells"*
Iordanov MS, Ryabinina OP, Magun BE
- 5:00 W10.7 *"Interferon-alpha suppresses activation of nuclear transcription factors NF-kappaB and AP-1, and potentiates TNF-induced apoptosis"*
Manna SK, Mukhopadhyay A, Aggarwal BB

8:00 pm **CLEVELAND ORCHESTRA (tickets limited)**



New ISICR Members

The ISICR welcomes the following new members.
Contact information can be obtained from the Headquarters Office

Alex Almansan	Cleveland, OH	Tuula A. Nyman	Turku, Finland
David C.M. Chan	Toronto, Canada	Theoharis Panaretakis	Stockholm, Sweden
Gray K. Geiss	Seattle, WA	Katja Pokrovskaja	Stockholm, Sweden
Bendi Gong	Cleveland, OH	Theresa M. Rowe	Cleveland, OH
Celine Gongora	Bethesda, MD	Srijata Sarkar	Piscataway, NJ
Catherine M. Greene	Beaumont Dublin, Ireland	Swati S. Sathe	Cleveland, OH
Matthew P. Hardy	Melbourne, Australia	Nywana Siezemore	Cleveland, OH
Rune Hartmann	Cleveland, OH	Rhea Sumpter	Dallas, TX
Anna A. Hinek	Toronto, Canada	Tomohiko Tamura	Bethesda, MD
Mihail S. Iordanov	Portland, OR	Michael Y. Torgov	Seattle, WA
Nasir Z. Jamali	Brooklyn, NY	Hideki Tsujimura	Bethesda, MD
Bogna Jatzczak	Wroclaw, Poland	Shu-Zong Wang	Columbia, MO
Ana Jurgens	New York, NY	Zhengfu Wang	Cleveland, OH
Douglas J. Kawahara	Oakland, CA	John Wong	Portland, OR
Tatiana Kisseleva	New York, NY	Ying Xiang	Cleveland, OH
Andrea Kroeger	Braunschweig, Germany	Hongmei Yang	Cincinnati, OH
Jutta Lehmann	Munchen, Germany	Ming Zhong Yao	Shanghai, China
Geqing Li	Cleveland, OH	Weiming Yuan	Austin, TX
Bruce E. Magun	Portland, OR	J.J. Zhang	New York, NY
Catalin Mindrescu	New York, NY	Zhendong Zhao	Cleveland, OH
Van De V. Mira	Erembodegem, Belgium		

New ISICR Subcommittee

Clinical subcommittee

Hans Strander, Chair

John Kirkwood
Fernando Dianzani

Kathryn Zoon
Ernest Borden

Future ISICR Meetings

Oct. 6-11 2002

Torino, Italy

**Joint with the International Cytokine
Society, the Society of Leukocyte
Biology, and the European
Cytokine Society**

2003

Cairns, Australia

Support

ISICR

Renew Your
Membership
NOW!

Reviews of Interest

Akbar AN, Lord JM, Salmon M. IFN- α and IFN- β : a link between immune memory and chronic inflammation.

Immunology Today 21:337, 2000.

Ansel KM, Cyster JG.

Chemokines in lymphopoiesis and lymphoid organ development. *Current Op. in Immunol.* 13:172, 2001.

Aukrust P, Damas JK, Gullestad L, et al. Chemokines in myocardial failure – pathogenic importance and potential therapeutic targets. *Clin. Exp. Immunol.* 124: 343, 2001.

Biron CA. Interferons α and β as immune regulators-a new look. *Immunity* 14:661, 2001.

De Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta in cancer. *J. Natl. Cancer Inst.* 92:1388, 2000.

Fitzgerald KA, O'Neill LAJ. The role of the interleukin 1/Toll-like receptor superfamily in inflammation and host defence. *Microbes & Infection* 2:933, 2000.

Gadina M, Hilton D, Johnston JA, Morinobu A et al. Signaling by Type I and II cytokine receptors: ten years after. *Current Op. in Immunol.* 13:363, 2001.

Gillitzer R, Goebeler M.

Chemokines in cutaneous wound healing. *J. Leuk. Biol.* 69:513, 2001.

Guidotti LG, Chisari FV.

Cytokine-mediated control of viral infections. *Virology* 273:221, 2000.

Jankovic D, Liu Z, Gause WC.

Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. *Trends in Immunol.* 22:450, 2001.

Loetscher P, Clark-Lewis I.

Agonistic and antagonistic activities of chemokines. *J. Leuk. Biol.* 69:881, 2001.

Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulating gene expression. *Oncogene* 19:2619, 2000.

Sato M, Taniguchi T, Tanaka, N. The interferon system and interferon regulatory factor transcription factors – studies from gene knockout mice. *Cytokine & Growth Factor Rev.* 12: 133, 2001

Thelen M. Dancing to the tune of chemokines. *Nat. Immunol.* 2:129, 2001.

Waldmann TA, Dubois S, Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for Immun-otherapy. *Immunity* 14:105, 2001.

Clinical Trials

Clinical Trials on this list were obtained at:

<http://www.centerwatch.com/search.asp>

<http://clinicaltrials.gov>

Study of long term **PEG Intron** versus colchicine for patients who have failed to respond to Rebetrone/ Interferon with advanced fibrosis and cirrhosis secondary to Hepatitis C. Contact: Gail Danhour, Rocky Mountain Clinical Research, Inc., Golden, CO Tel: 303-279-1550 Email: GailRMCR@aol.com

High Dose **Beta Interferon 1a** for the treatment of Inclusion Body Myositis (IBM).

Contact: Laura Herbelin, University of Kansas Medical Center Research Institute, Kansas City, KS Tel: 913-588-6970 Email: lherbelin@kumc.edu

A research study to evaluate **Interferon gamma-1b** in addition to conventional MAC treatment in patients with pulmonary Mycobacterium avium complex (MAC) infection. Contact: Study Coordinator, Tucson, AZ Tel: 866-630-0890 Email: Intermune1@clinimetrics.com

A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study of the safety and antifungal activity of subcutaneous recombinant **interferon- γ 1b** in conjunction with standard therapy in patients with acute cryptococcal meningitis. Contact: Annette C.

Reboli, The Cooper Health System, Camden, NJ Tel: 856-757-7767

Multicenter Open-Label Study to Evaluate the Safety and Efficacy of **DAB389IL-2** in

Cutaneous T-Cell Lymphoma Patients following Protocol 93-04-11 or who meet the Requirements for Protocol 93-04-11, except have Biopsy-Documented CTCL that Does Not Express CD25 (93-04-14). Contact: Tracy Bell, New England Medical Center Boston, MA Tel: 617-636-5558

NBI-3001-0001, NBI-BB-IND-7004, SLUMC-11350 - Phase II Randomized Study of **Interleukin-4(38-37)-PE38KDEL**

Immunotoxin (NBI-3001) Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme. Contact: Richard Bucholz, St. Louis University Health Sciences Center, Saint Louis, MO. Tel: 314-577-8797 or Anthony Asher, Charlotte Neurosurgical Associates, Charlotte, NC. Tel: 704-376-1605

36 wk subcutaneous **interleukin 11** in patients with mild-moderate Crohn's, either new onset or in flare. Contact: Paul McGowan, South Puget Sound Clinical Research Center, Olympia, WA Tel: 360-754-6704 Email: spscre@pop.halcyon.com

ACTG 325 - **Interleukin 12** (rhIL-12) for patients with HIV infection. Contact: Teri Flynn, Massachusetts General Hospital Boston, MA Tel: (617) 726-3819 Email: tflynn@partners.org

Study of **Interleukin 12** for plateau phase multiple myeloma. Contact: Martha Q. Lacy or Cindy Cox, The Mayo Clinic Rochester, MN Tel: 507-284-2511

00-D-0168- Safety and Efficacy of a **TNF Receptor Fusion Protein** for Injury-Induced Inflammation and Sequelae. Contact: National Institute of Dental And Craniofacial Research Institute, Bethesda, MD Tel: 1-800-411-1222 Email: prpl@mail.cc.nih.gov

99-EI-0047 - The Safety and Efficacy of a **Tumor Necrosis Factor Receptor Fusion Protein** on Uveitis Associated with Juvenile Rheumatoid Arthritis. Contact: National Eye Institute, Bethesda, MD, Tel: 1-800-411-1222 Email: prpl@mail.cc.nih.gov

98-C-0137 - Evaluation of the Association of Polymorphisms in the Innate Immune System (mannose binding lectin, Fc-gamma receptor IIa and IIb, Fc-gamma receptors IIIa and IIIb, myeloperoxidase, **tumor necrosis factor-alpha and -beta, interleukin 1A and 1B, interleukin-1 receptor antagonist, interleukin-10, NRAMP-1, chitotriosidase, and chemokine receptor 5**) with the Risk for Cryptococcus neoformans Infection in Patients not Infected with HIV and Complications Associated with Cryptococcus neoformans Infection. Contact: National Cancer Institute Bethesda, MD Tel: 1-800-411-1222 Email: rpl@mail.cc.nih.gov

98-I-0049 - To investigate the in vivo cytokine and chemokine production patterns of human skin in patients with mastocytosis and compare these findings to those of patients with atopic dermatitis and to health volunteers, using the suction blister technique. The cytokines/chemokines of interest in this study are **stem cell factor (SCF), interleukin (IL)-3, IL-4, IL-6, IL-9, IL-10, TNF-alpha, TGF-beta, MCP-1 and RANTES**, all of which have been shown to take part in the proliferation, differentiation or chemotaxis of mast cells. Contact: National Institute of Allergy and Infectious Diseases Bethesda, MD Tel: 1-800-411-1222 Email: prpl@mail.cc.nih.gov

94-I-0203 - Peripheral Blood T Cell Cytokine (**IL-4, IL-5, IFN-gamma**) Production in Asthmatics. Contact: National Institute of Allergy and Infectious Diseases Bethesda, MD, Tel: 1-800-411-1222 Email: prpl@mail.cc.nih.gov

UAB-GCRC-617 - Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture. Patients' blood is analyzed for **tumor necrosis factor alpha, tumor necrosis factor beta, mannose binding protein, interleukin-1 receptor antagonist**, and bcl-2. Contact: Graciela S. Alarcon, University of Alabama Comprehensive Cancer Center, Birmingham, Al Tel: 205-934-3883

Chocoholic tips and quotes

If you've got melted chocolate all over your hands, you're eating it too slowly.

Chocolate covered raisins, cherries, orange slices & strawberries all count as fruit, so eat as many as you want.

The problem: How to get 2 pounds of chocolate home from the store in hot car. **The solution:** Eat it in the parking lot.

A nice box of chocolates can provide your total daily intake of calories in one place. Isn't that handy?


If you can't eat all your chocolate, it will keep in the freezer. But if you can't eat all your chocolate, what the heck is wrong with you?

If calories are an issue, store your chocolate on top of the fridge. Calories are afraid of heights, and they will jump out of the chocolate to protect themselves.

Q. If I eat equal amounts of dark chocolate and white chocolate, is that a balanced diet? A. Don't forget the milk chocolate.

Chocolate has many preservatives. Preservatives make you look younger.

Money talks. Chocolate sings.



Public Alignment Database and Web Submission Tool

<http://srs.ebi.ac.uk/>
<http://www.ebi.ac.uk/embl/Submission/>

*EMBL-Align Database - a repository for nucleotide and protein alignments generated from phylogenetic and population studies
<http://srs.ebi.ac.uk/>

*WEBIN-Align Tool – New web based tool for Submission, Annotation and Display of Sequence Alignment Data
<http://www.ebi.ac.uk/embl/Submission/>

To satisfy a growing need for the permanent electronic storage of secondary alignment data from comparative genomics and phylogenetics, the EMBL group

are pleased to announce the launch of a new public alignment database, 'EMBL-Align' and web based alignment submission tool, WEBIN-Align'.

This new tool and database has:

* Interactive WEB BASED INTERFACE for NUCLEOTIDE and PROTEIN alignment data.

* Common alignment formats are accepted including all Clustal, NEXUS (interleaved), Phylip, FASTA and MSF via a secure UPLOAD FACILITY.

* A CONSERVED FLAT FILE structure between alignment data (EMBL-Align) and primary sequence data (EMBL) facilitates consistent display, storage and indexing of alignment data.

See example:

ftp://ftp.ebi.ac.uk/pub/databases/embl/align/ALIGN_000018.dat

* DYNAMIC LINKS TO PRIMARY DATA in EMBL/DDBJ/Genbank and SWISS-PROT

* FEATURE TABLE options for nucleotide sequence alignments allow users to define boundaries of interest.

See annotation examples:

<http://www3.ebi.ac.uk/Services/webin/help/webin-align/annotation/>

* CURATION of EMBL-Align is performed by the same biologists as the EMBL database.

* UNIQUE ALIGNMENT ACCESSION NUMBERS are assigned for alignments within 2 working days pending review by EMBL biologist

(eg. ALIGN_000001).

* Data is downloadable as an EMBL-Align flat file or Clustal W alignment only format.

* Alignment data can be retrieved from EBI SRS Server in a variety of Display formats eg. JalView (Java Multiple Alignment Editor)

This database and submission tool represent a systematic and universal method of dealing with alignment data from which conclusions are drawn thereby requiring long term storage.

If you have any questions about the EMBL-Align database and Webin-Align please e-mail the Webin-Align Administrators at align@ebi.ac.uk.

Kind regards

EMBL-Align Database team

This work was supported by EMBL and the European Commission. Webin-Align Administrators: Evelyn Camon & Helen Parkinson
Webin-Align Developer: Vincent Lombard.

The Cancer Research Portfolio
(<http://researchportfolio.cancer.gov>)

The Cancer Research Portfolio, a new U.S. National Cancer Institute Web site, contains information on approximately 9000 research projects, including grants, contracts, and clinical trials active in Fiscal Year 2000. Using the Web site, users can search, browse, and sort NCI-supported research in ways never possible before. For example...

- NCI division, program, and intramural staff can view their research portfolios online and see related research supported across the Institute.

- NCI staff can more easily answer press, advocate, or Congressional inquiries about NCI research both in terms of disease specific research and NCI research in specific Scientific areas.

- Research scientists can more easily identify scientists doing similar work, as well as contacts for multidisciplinary research and collaborations.

- Cancer patients and advocates can see exactly what NCI is supporting related to their disease, with easy links to PDQ and clinical trials information.

- Congressional staff can view NCI research supported in their state.

Visitors to this site can view and retrieve information on NCI disease-specific research by choosing from over 75 different site categories and seven different scientific areas. The scientific areas follow the Common Scientific Outline (CSO), a recently standardized coding system organized around 7 broad scientific areas.

You can query either by type of cancer (breast, prostate, lung, etc.) or by type of cancer research (biology, etiology, prevention, treatment, etc.). NCI-supported training projects and FY 2001 research projects and clinical trials will be added to the site in the near future. Visit the "About this Site" and "Frequently Asked Questions" links on the site for more information.

Bookmark the site at

<http://researchportfolio.cancer.gov>

For more information or to share feedback, contact the NCI Office of Scientific Planning and Assessment.

Database of Interacting Proteins

<http://dip.doe-mbi.ucla.edu/jdip>

It's our pleasure to announce the first public release of JDIP - our new, stand-alone, Java-based interface to the DIP database (Database of Interacting Proteins; <http://dip.doe-mbi.ucla.edu>). It's still

got a lot of rough edges here and there but it seems to be quite stable so we think there's no reason not to release it. The program provides the same functionality as the original, Web-based interface to DIP but with quite a few extras including local storage of protein interaction networks, both, in graphical and XML-based formats, custom rendering and annotation of interaction graphs and embedded scripting language (Python, to be exact).

It might be of interest that the format of the data files (specified as an XML schema – to be found at <http://dip.doe-mpi.ucla.edu/jdip/jin.xsd>) is generic enough to allow JDIP to serve as an interface/ visualization program dealing with data completely unrelated to protein-protein interaction - is all the matter of writing appropriate (either server or client side) scripts... Please, direct questions/ suggestions/bug reports/etc to jdip@mpi.ucla.edu

Lukasz Salwinski (and the DIP database maintainers)
lukasz@mpi.ucla.edu

ISYS integration platform for Bioinformatics resources.
<http://www.ncgr.org/research/isys>

An evaluation copy of the software can be downloaded for free. While the system is free in general for non-commercial use, those interested in commercial applications should contact us for licensing information (isys@ncgr.org).

In addition to the components provided in our Developers'

Release of last January, the ISYS platform now includes extensions that allow integration of web-based resources with client-side software tools. We are excited to say that widely-used resources such as Entrez/PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>); SGD (<http://genome-www.stanford.edu/Saccharomyces>); Flybase (<http://flybase.bio.indiana.edu>); Genscan (<http://genes.mit.edu/GENSCAN.html>); and even Google (<http://www.google.com>) can now be made to exchange data to and from ISYS components with a few clicks of the mouse. We think the system is considerably strengthened by the capacity to integrate customizable, client-side tools with powerful, Internet services for data and analysis.

Components that have been available for use with ISYS since the last release include NCGR's Sequence Viewer, Similarity Searcher, and Table Viewer, and "wrapped" versions of the maxdView gene expression viewer (<http://bioinf.man.ac.uk/microarray>) and BDGP Gene Ontology Browser (<http://www.fruitfly.org>). See <http://www.ncgr.org/research/isys/components.html> for a description of these components.

ISYS provides an intuitive, graphical environment for bioinformatics discovery, by integrating heterogeneous and separately-developed software components. Using the Broker and Event Channel software architectural

patterns, it allows components to exchange "services" and to synchronize their behavior without being so tightly coupled that one component constrains the evolution of the others. The user of the system can "plug-and-play" among available components, to establish a configuration appropriate for his or her needs. Java programmers can relatively easily add new components by designing them from scratch, or by "wrapping" existing software.

The specifications for the ISYS API and other resources for software developers are available at <http://www.ncgr.org/research/isys/devrel.html>.

For an illustration of the new version of ISYS in action, see the "Click-By-Click Tour" at <http://www.ncgr.org/research/isys/scenario.html>.

Adam Siepel
co-leader, ISYS Project

Molecular Dynamics Salon
<http://www.ks.uiuc.edu/Services/MDSalon/>

The Theoretical Biophysics Group at the University of Illinois is an NIH Resource for Macromolecular Modeling and Bioinformatics. We serve the structural biology community by developing software and methods, and through direct collaboration with experimental biologists. We have seen the need for an interactive forum for users of molecular dynamics software and techniques, of all experience levels, to exchange views and expertise.

As a service to the molecular modelling community, we are constructing an online gathering place. The first areas of MDSalon available are discussion forums catering separately to developers of MD software and to those whose are primarily interested in its application to simulations. There are currently two main forums, but more will be added as popular sub-topics emerge. We will also be adding databases of software and user-contributed examples, as well as a special developers' area featuring collected benchmarks.

PIR-International Protein Sequence Database (PIR-PSD)

Release 68.0 in XML, Containing 219,241 Annotated Entries
<http://pir.georgetown.edu>

The PIR-PSD Release 68.0 is downloadable from the FTP site at the following locations:

- (1) For XML and DTD Files:
ftp://nbrfa.georgetown.edu/pir/databases/pir_xml/
- (2) For FASTA Sequence Files:
ftp://nbrfa.georgetown.edu/pir/databases/pir_fasta/
- (3) For CODATA Format Data Files:
ftp://nbrfa.georgetown.edu/pir/databases/pir_codata/
- (4) For NBRF Format Data Files:
ftp://nbrfa.georgetown.edu/pir/databases/pir_nbrf/

Announcing the upgrade of the PIR web site

<http://pir.georgetown.edu/>

The PIR Web site has been upgraded with a user-friendly navigation system, new search tools, and new graphical interfaces.

- Database Information Page: Information on PIR-PSD and Auxiliary Databases:

<http://pir.georgetown.edu/pirwww/dbinfo/dbinfo.html>

- Search Sequence and Database Retrieval:

<http://pir.georgetown.edu/pirwww/search/searchseq.html>

- Updated PIR-PSD Retrieval System:

<http://pir.georgetown.edu/pirwww/search/textpsd.shtml>

New feature of the PIR-PSD: Batch Retrieval that allows users to retrieve multiple protein sequences in PIR-PSD

- New HMM (Hidden Markov Model) Domain/Motif Search:

<http://pir.georgetown.edu/pirwww/search/pirhmm.html>

Search a query sequence against HMM profiles for PIR or Pfam domains or iProclass motifs, or build a HMM profile, and search the profile against the PIR-PSD.

Staden Package - 2001.0b7.

<http://www.mrc-lmb.cam.ac.uk/pubseq/>

The most significant change in this release is the merging of nip4 and sip4 into one program (named "spin") which includes a graphical user interface to the EMBOSS tools. Spin therefore allows EMBOSS plots to be superimposed, scrolled and scaled in the same manner as the existing nip4 and sip4 plots.

In addition to this Gap4 has many improvements, including speed increases for larger projects (for example we have sites using 200,000 sequences producing over 7Mb of

consensus sequence), an improved Find Internal Joins, new searches, longer sequence names and even more sequences allowed (now up to 99,999,999), the ZTR trace file format, a test-version of the new automatic experiment suggestion tools, and bug fixes.

The beta release does not require a licence, but it expires on the 11th of November. For more details see:

<http://www.mrc-lmb.cam.ac.uk/pubseq/news.2001.html>

The Staden Package development team James Bonfield (jkb@mrc-lmb.cam.ac.uk) Tel: 01223 402499 Fax: 01223 213556

Medical Research Council - Laboratory of Molecular Biology, Hills Road, Cambridge, CB2 2QH, England.

Also see Staden Package WWW site at <http://www.mrc-lmb.cam.ac.uk/pubseq/>



The only fool
bigger than
the person
who knows it
all is the
person who
argues with
him.

— Stanislaw Jerszy Lec

IDENTIFIED MUTATIONS FOR GENETIC TESTING

The Coriell Cell Repositories through the NIGMS Human Genetic Cell Repository and the NIA Aging Cell Repository have a collection of more than 600 cell lines and DNA samples representing 83 diseases with characterized mutations which could be used as standards. These include diseases caused by expansion of trinucleotide repeats, such as dentatorubral-pallidoluysian atrophy (for which three samples with known repeats are available); myotonic dystrophy (13); Friedreich ataxia (10); fragile X syndrome (26); Huntington Disease (13); SCA1 (2); and SCA3 (2).

The collection also includes 40 different mutations in the CFTR gene, 20 unique mutations in the BRCA1 gene, 6 mutations in the BRCA2 gene, and 4 mutations in the APC gene. Samples from patients with hemochromatosis (19), muscular dystrophy (11), and spinal muscular atrophy (3) have also been molecularly characterized. In addition, specimens carrying the factor V Leiden mutation (4), the MTHFR thermolabile variant (3), and the 20210G-A polymorphism in the prothrombin gene (2) are also included in the collection. Standards are also available for apolipoprotein E and Rh D genotyping. Finally, the collections include five cell lines with mutations in multiple genes: two have mutations in three different genes, e.g., one with mutations in MTHFR, F2, and F5, and a second with mutations in MTHFR, F2, and HFE, and three cell lines have identified mutations in two genes, e.g., MTHFR and DMPK, HFE and F5, and CFTR and HFE. The samples in these resources, validated by certified expert molecular laboratories, are valuable reagents for laboratories performing molecular genetic testing and may also be useful for quality assurance programs. Detailed information about these samples, including ordering instructions, is available in an electronic catalog (<http://locus.umdj.edu/ccr>).

For additional information, contact:

Coriell Cell Repositories
Coriell Institute for Medical Research
401 Haddon Avenue
Camden, NJ 08103

Telephone:

(800) 752-3805 in the United States
(609) 757-4848 from other countries
FAX: (609) 757-9737
e-mail: ccr@arginine.umdj.edu

Jeanne C. Beck, Ph.D.
Deputy Director
Coriell Cell Repositories
401 Haddon Avenue
Camden, New Jersey 08103
Voice: 856-757-4847
Fax: 856-757-9737
e-mail: jbeck@umdj.edu

THANK YOU

Mr. And Mrs. Seymour Milstein
for your continuing support of
the ISICR!!!!

**The road to
success is
constantly
under
construction.**

ISICR POLL

Please fax your responses to the ISICR Office at 301-530-7049 or email your responses to ISICR@faseb.org

1. I would be interested in joining an ISICR email ListServ for the expressed purpose of rapid communication within the ISICR, including requests for reagents and/or technical assistance.

Yes _____

No _____

2. I would prefer to receive the ISICR member directory as:

Printed copy _____

CD-Rom _____

3. I would prefer to receive the ISICR newsletter as:

Printed copy _____

Email as a PDF file _____

ASSOCIATE EDITORS NEEDED!!!

The ISICR newsletter needs additional associate editors to help with regular columns, special features, etc. We also welcome volunteers from outside the US to contribute information relevant to interferon and cytokine research in their home countries. Think of the status in being an ISICR newsletter editor! Contribute to the ISICR and do something good by joining the editorial team! Maybe someone will send you chocolate. Contact Howard Young via email (youngh@ncifcrf.gov) for assignments.

**THE TROUBLE WITH
DOING NOTHING
IS THAT YOU NEVER
KNOW WHEN
YOU ARE**

FINISHED.

First Virtual Conference in Genomics and Bioinformatics

October 15 & 16, 2001

At World-Wide Access Grid Locations

Sequencing projects and genomics research has led to an explosive rate of data accumulation and to a shift in the way biological research is conducted. Bioinformatic tools of the post-genome era are providing new insights about gene expression patterns, intron/exon structure, post-translational changes and protein interactions as well as phylogenetic relationships. Parallel analysis of thousands of genes using microarray technology has become a multi-disciplinary endeavor in which unsupervised and supervised learning is applied for gene expression clustering and/or classification. Although genomic technologies offer an enormous scientific potential to understand organisms at the molecular level, new challenges on the horizon are envisioned. There is a need for improvement of microarray technology, data standardization, and tools for integration of multiple databases and data mining. Other necessary needs include the improvement of bioinformatic tools and statistical approaches for sequence analysis, gene annotation, categorization of protein families, protein-protein interactions, and phylogenetic studies.

The goal for the First Virtual Conference in Genomics and Bioinformatics is to increase the exchange of ideas and establish new ways of interaction and collaboration among scientists around the world.

For the 2001 Virtual Conference, topics include:

Functional Genomics
Structural Genomics
Computational Approaches for Gene Expression Analysis
Metabolic Profiling
Genomic Data Standardization and Management
Implications of Genomic Research
Proteomics

National Institute of Standards and Technology
North Dakota State University
Stanford University
UC Berkeley

Resources
National Institute of Standards and Technology
North Dakota State University
Ohio State University
Stanford University
UC Berkeley

Invited speakers and Participation:

For the First Conference, invited speakers and reviewers represent institutions including:

Argonne National Laboratory
Brookhaven National Laboratory
Cold Spring Harbor Laboratory
First Genetic Trust, Inc.
Massachusetts Institute of Technology
National Center for Genome Resources

Although registration is required, there are no required registration fees to participate in the conference. To participate at the Fargo Access Grid Node or one of several other Nodes around the world, please register in an electronic catalog (<http://locus.umdj.edu/ccr>).

Abstract and Papers:

In addition to the invited presentations, we invite participants to 3 cm margins on all four sides on letter size paper. An electronic document session will be scheduled following the conference to allow the maximum participation between the attendees and the authors.

Accepted documents as well documents submitted by invited speakers will be available in electronic version in the "Proceedings of the Virtual Conferences of Genomics and Bioinformatics."


Deadline: August 31, 2001 for abstracts
Deadline: September 21, 2001 complete documents

Link to submit your abstract
<http://www.ndsu.nodak.edu/virtual-genomics/abstract.htm>

Useful links:
Access Grid locations in the US and around the world:
<http://www-fp.mcs.anl.gov/fl/accessgrid/ag-nodes.htm>

Suscribe to our e-mail list
<http://listserv.nodak.edu/scripts/wa.exe?SUBED1=virtual-genomics&A=1>

Registration to attend the meeting in Fargo, North Dakota:
<http://www.ndsu.nodak.edu/virtual-genomics/registration.htm>

E-mail your questions to
Edward_Deckard@ndsu.nodak.edu
Willy_Valdivia@ndsu.nodak.edu 

PRIMATE MATERIALS AVAILABLE FOR RESEARCH

The National Institute on Aging (NIA) Aging Cell Repository has assembled panels of primate materials for distribution. These panels contain samples from the following nonhuman primates: ring-tailed lemur, black-handed spider monkey, woolly monkey, red-bellied tamarin, pig-tailed macaque, rhesus macaque, orangutan, gorilla, chimpanzee, and bonobo. These samples are available either as fibroblast cultures or DNA. Additional information can be obtained at <http://locus.umdj.edu/nia> or by contact with the Repository.

The NIA Aging Cell Repository
Coriell Cell Repositories
401 Haddon Avenue
Camden, NJ 08103

Telephone: 800-752-3805 within the United States
856-757-4848 from other countries
Fax: 856-757-9737
e-mail: ccr@arginine.umdj.edu

Jeanne C. Beck, Ph.D.
Deputy Director
Coriell Cell Repositories
401 Haddon Avenue
Camden, New Jersey 08103
Voice: 856-757-4847
Fax: 856-757-9737
e-mail: jbeck@umdj.edu

**INTERNATIONAL SOCIETY FOR INTERFERON
AND CYTOKINE RESEARCH**

9650 Rockville Pike
Bethesda, MD 20814-3998
U.S.A.

NON-PROFIT ORG.
U.S. POSTAGE
PAID
BETHESDA, MD 20814
PERMIT NO. 4982